LymphoSeek® (technetium Tc 99m tilmanocept)

Question:
Could you please tell us how to code the FDA approved (March 13, 2013) Lymphatic Mapping procedure and radiopharmaceutical LymphoSeek? This to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma? Additionally, on June 13, 2014 the FDA expanded use for guiding sentinel lymph node (SNL) biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity.

Answer:
Please Login as a SNMMI Member to access the answers to the Coding and Reimbursement Q&As.

The opinions referenced are those of the members of the SNMMI Coding and Reimbursement Committee and their consultants based on their coding experience. They are based on the commonly used codes in Nuclear Medicine, which are not all inclusive. Always check with your local insurance carriers as policies vary by region. The final decision for the coding of a procedure must be made by the physician considering regulations of insurance carriers and any local, state or federal laws that apply to the physicians practice. The SNMMI and its representatives disclaim any liability arising from the use of these opinions.